Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Cytometix Inc
Profile last edited on: 1/22/13      CAGE: 4GJF7      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2004
First Award
2007
Latest Award
2008
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

756 North Milwaukee Street
Milwaukee, WI 53202
   (414) 727-1726
   navin@tsearlyventures.com
   www.cytometix.com
Location: Single
Congr. District: 04
County: Milwaukee

Public Profile

With ties to the Medical College of Wisconsin, Cytometix is a pharmaceutical development company that is developing CMX-020, a new molecular entity to treat pain. CMX-020 is similar in chemical structure to AM404, the active metabolite in acetaminophen. In animal studies, CMX-020 can be dose titrated to provide levels of analgesia equivalent with traditional opioids. CMX-020 is not a µ-opioid receptor agonist

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$139,965
Phase II Dollars
$34,548
Total Awarded
$174,513

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2008 1 NIH $174,513
Project Title: Development of Cytochrome P450 Therapy for Chronic Pain

Key People / Management

  Lane Brostrom -- President

  John Luellwitz -- Director of Business Development

Company News

There are no news available.